Home | Welcome to Contract Pharma   
Last Updated Friday, October 31 2014
Print

Catalent, Pure MHC in Product Development Pact



Published November 21, 2013
Related Searches: catalent Manufacturing Development Preclinical
Catalent Pharma Solutions and Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, have signed a product development agreement under which Catalent will develop a humanized version of Pure MHC’s RL21A antibody and engineer a cell line to express the antibody using its GPEx technology. Catalent will subsequently produce purified monoclonal antibodies to support preclinical development with humanized RL21A for the treatment of cancer. 
 
“We are confident that our partnership with Catalent will result in the development of the enhanced antibodies necessary to help get RL21A into the clinic more quickly,” said Thomas Harlan, chief executive officer of Pure MHC, “Our ultimate goal for this technology is to one day provide cancer patients with a treatment option that is safer and more effective than those available today.”
 
“We are delighted to again demonstrate how GPEx technology, together with Catalent’s development and manufacturing expertise, can support development of novel therapies and enable companies such as Pure MHC to validate their unique target screening methodology,” said Jonathan Arnold, vice president, general manager of Catalent’s Advanced Delivery Technologies business.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On